Is Avalo Therapeutics, Inc. (AVTX) a Buy, Sell, or Hold?
NASDAQ : AVTX
Avalo Therapeutics, Inc.
$18.0162 USD
-$0.03 (-0.19%)
- Volume
- 170.36K
- Average Volume
- 1.94M
- Market Capitalization
- $203.48M
- P/E Ratio
- -3.09
- Dividend Yield
- 0.00%
- Price Target
- $45.00
- Year High
- $24.27
- Year Low
- $7.87
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.66
Company Overview
NASDAQ
Garry A. Neil
Biotechnology
Healthcare
AVTX
33
US
USD
Liquidity Metrics
0.03
7.66
7.66
2.15
0.00
Sales & Valuation
$59000
3448.76
5.30
-3.41
-2.97
Profitability
-$5.84
-$78.26M
-143627.12%
-143340.68%
-97.55%
-84.84%
P/E Metrics
-3.09
0.03
0.03
Analyst Price Target & Rating
$45.00
$60.00
$34.00
2/5
9 Analysts
-59.96%
Financial Health Scores
-4.51
1/9
$77.23M
$99.88M
$31.56M
-$84.57M
Key Metrics (TTM)
$181.2M
3071.17
-2.15
7.66
-97.55%
-89.33%
-23.35%
-29.28%
-6 days
Company Executives
| Name | Title |
|---|---|
| Dino C. Miano | Senior Vice President of CMC & Technical Operations |
| Christopher Ryan Sullivan | Chief Financial Officer & Head of Investor relations |
| Barbara S. Slusher | Founder and Member of Scientific Advisory Board |
| Solomon H. Snyder | Founder and Chairman of Scientific Advisory Board |
| Paul C. Varki | Chief Legal Officer |
| Jennifer Riley | Chief Strategy Officer |
| Ashley Ivanowicz | Senior Vice President of Human Resources |
| Garry A. Neil | President, Chief Executive Officer & Director |
| Mittie Doyle FACR | Chief Medical Officer |
| Taylor Boyd | Chief Business Officer |
Poll Results
No votes yet today — be the first to share your view!
About Avalo Therapeutics, Inc. (NASDAQ:AVTX) Stock
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monocl ... onal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
2026-07-22 07:00:00
WAYNE, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will participate in the “Honing in on Hidradenitis” panel at the virtual BTIG Biotechnology Conference on Wednesday, July 29, 2026, at 10:30 am ET. Management will also host one-on-one investor meetings during the conference.
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
2026-07-07 07:00:00
WAYNE, Pa. , July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will host one-on-one investor meetings during the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston.
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
2026-07-07 07:00:00
WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will host one-on-one investor meetings during the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston.
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes
2026-06-26 07:00:00
WAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that it will be added to the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 26, 2026.
Avalo Therapeutics Appoints Ron Philip to Board of Directors
2026-06-23 07:00:00
WAYNE, Pa., June 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the appointment of Ron Philip to its Board of Directors. Mr. Philip brings more than 30 years of biopharmaceutical leadership to the Board, with a deep background in commercial and strategic execution, including guiding multiple companies through product launches and billion dollar exits.
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody
2026-06-16 07:00:00
WAYNE, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody (mAb) with the potential for development in hidradenitis suppurativa (HS) as well as additional inflammatory disorders.
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
2026-05-22 16:01:00
WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company granted an inducement award consisting of an option to purchase 34,000 shares of its common stock to one new employee (the “Option”). The award was approved by the Compensation Committee of the Board of Directors as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
2026-05-13 07:00:00
WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced business updates and first quarter 2026 financial results.
Frequently Asked Questions
-
What is the current Avalo Therapeutics, Inc. (AVTX) stock price?
-
Avalo Therapeutics, Inc.(NASDAQ:AVTX) stock price is $18.0162 in the last trading session. During the trading session, AVTX stock reached the peak price of $24.27 while $7.87 was the lowest point it dropped to. The percentage change in AVTX stock occurred in the recent session was --0.19% while the dollar amount for the price change in AVTX stock was -$0.03.
-
AVTX's industry and sector of operation?
-
The NASDAQ listed AVTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AVTX?
-
Dino C. Miano | Senior Vice President of CMC & Technical Operations
Christopher Ryan Sullivan | Chief Financial Officer & Head of Investor relations
Barbara S. Slusher | Founder and Member of Scientific Advisory Board
Solomon H. Snyder | Founder and Chairman of Scientific Advisory Board
Paul C. Varki | Chief Legal Officer -
How many employees does AVTX have?
-
Number of AVTX employees currently stands at 33. AVTX operates from 1500 Liberty Ridge Drive, Wayne, PA 19087, US.
-
Link for AVTX official website?
-
Official Website of AVTX is: https://www.avalotx.com
-
How do I contact AVTX?
-
AVTX could be contacted at phone #410 522 8707 and can also be accessed through its website. AVTX operates from 1500 Liberty Ridge Drive, Wayne, PA 19087, US.
-
How many shares of AVTX are traded daily?
-
The average number of AVTX shares traded daily for last 3 months was 1.94M.
-
What is the market cap of AVTX currently?
-
The market value of AVTX currently stands at $203.48M with its latest stock price at $18.0162